TRAW Relative Valuation
TRAW's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TRAW is overvalued; if below, it's undervalued.
Historical Valuation
Traws Pharma Inc (TRAW) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -13.82. The fair price of Traws Pharma Inc (TRAW) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.07
Fair
-59.00
PE
1Y
3Y
5Y
Trailing
Forward
-0.35
EV/EBITDA
Traws Pharma Inc. (TRAW) has a current EV/EBITDA of -0.35. The 5-year average EV/EBITDA is -0.70. The thresholds are as follows: Strongly Undervalued below -6.73, Undervalued between -6.73 and -3.71, Fairly Valued between 2.31 and -3.71, Overvalued between 2.31 and 5.32, and Strongly Overvalued above 5.32. The current Forward EV/EBITDA of -0.35 falls within the Historic Trend Line -Fairly Valued range.
-0.38
EV/EBIT
Traws Pharma Inc. (TRAW) has a current EV/EBIT of -0.38. The 5-year average EV/EBIT is -0.75. The thresholds are as follows: Strongly Undervalued below -6.92, Undervalued between -6.92 and -3.84, Fairly Valued between 2.34 and -3.84, Overvalued between 2.34 and 5.43, and Strongly Overvalued above 5.43. The current Forward EV/EBIT of -0.38 falls within the Historic Trend Line -Fairly Valued range.
6.02
PS
Traws Pharma Inc. (TRAW) has a current PS of 6.02. The 5-year average PS is 181.77. The thresholds are as follows: Strongly Undervalued below -371.38, Undervalued between -371.38 and -94.80, Fairly Valued between 458.35 and -94.80, Overvalued between 458.35 and 734.92, and Strongly Overvalued above 734.92. The current Forward PS of 6.02 falls within the Historic Trend Line -Fairly Valued range.
-2.31
P/OCF
Traws Pharma Inc. (TRAW) has a current P/OCF of -2.31. The 5-year average P/OCF is 0.02. The thresholds are as follows: Strongly Undervalued below -0.85, Undervalued between -0.85 and -0.41, Fairly Valued between 0.45 and -0.41, Overvalued between 0.45 and 0.88, and Strongly Overvalued above 0.88. The current Forward P/OCF of -2.31 falls within the Strongly Undervalued range.
0.10
P/FCF
Traws Pharma Inc. (TRAW) has a current P/FCF of 0.10. The 5-year average P/FCF is 0.27. The thresholds are as follows: Strongly Undervalued below -1.79, Undervalued between -1.79 and -0.76, Fairly Valued between 1.30 and -0.76, Overvalued between 1.30 and 2.33, and Strongly Overvalued above 2.33. The current Forward P/FCF of 0.10 falls within the Historic Trend Line -Fairly Valued range.
Traws Pharma Inc (TRAW) has a current Price-to-Book (P/B) ratio of 3.31. Compared to its 3-year average P/B ratio of 0.00 , the current P/B ratio is approximately 75855.93% higher. Relative to its 5-year average P/B ratio of 2.07, the current P/B ratio is about 59.88% higher. Traws Pharma Inc (TRAW) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -163.39%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -115.33% , the current FCF yield is about -100.00% lower.
3.70
P/B
Median3y
0.00
Median5y
2.07
-115.46
FCF Yield
Median3y
-163.39
Median5y
-115.33
Competitors Valuation Multiple
The average P/S ratio for TRAW's competitors is 0.00, providing a benchmark for relative valuation. Traws Pharma Inc Corp (TRAW) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TRAW decreased by 73.42% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.74 to -1.71.
The secondary factor is the Revenue Growth, contributed -100.00%to the performance.
Overall, the performance of TRAW in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Traws Pharma Inc (TRAW) currently overvalued or undervalued?
What is Traws Pharma Inc (TRAW) fair value?
How does TRAW's valuation metrics compare to the industry average?
What is the current P/B ratio for Traws Pharma Inc (TRAW) as of Dec 05 2025?
What is the current FCF Yield for Traws Pharma Inc (TRAW) as of Dec 05 2025?
What is the current Forward P/E ratio for Traws Pharma Inc (TRAW) as of Dec 05 2025?